Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases-page1

ALL YEAR

2026/01/22

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (
2026/01/04

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Co
2026/01/04

Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the dire
2026/01/04

SINOVAC Secures Exclusive 2026 Influenza Vaccine Supply Contract in Chile

BEIJING, Jan. 4, 2026 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the

Previous page1Next page Go to No.